EICHORCondition: Melanoma · Sponsor: Bristol-Myers Squibb
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Local Institution - 0088 | Birmingham, Alabama, United States | — |
| Local Institution - 0126 | Tucson, Arizona, United States | — |
| Local Institution - 0087 | Springdale, Arkansas, United States | — |
| Local Institution - 0080 | Los Angeles, California, United States | — |
| Local Institution - 0077 | San Francisco, California, United States | — |
| Local Institution - 0119 | San Francisco, California, United States | — |
| Local Institution - 0122 | San Jose, California, United States | — |
| Local Institution - 0121 | Vallejo, California, United States | — |
| Local Institution - 0109 | Vallejo, California, United States | — |
| Local Institution - 0120 | Vallejo, California, United States | — |
| Local Institution - 0091 | Aurora, Colorado, United States | — |
| Local Institution - 0089 | Washington D.C., District of Columbia, United States | — |
+ 118 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04099251